BioTelemetry (NASDAQ:BEAT) Reaches New 12-Month Low at $39.33

BioTelemetry Inc (NASDAQ:BEAT) shares reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $39.33 and last traded at $39.40, with a volume of 12247 shares traded. The stock had previously closed at $40.90.

A number of equities analysts have recently issued reports on BEAT shares. ValuEngine downgraded BioTelemetry from a “hold” rating to a “sell” rating in a research report on Thursday, July 18th. Zacks Investment Research downgraded BioTelemetry from a “buy” rating to a “hold” rating in a research report on Friday, August 2nd. Lake Street Capital set a $90.00 price objective on BioTelemetry and gave the company a “buy” rating in a research report on Wednesday, July 31st. BidaskClub downgraded BioTelemetry from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 23rd. Finally, Sidoti dropped their price objective on BioTelemetry from $95.00 to $87.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $72.57.

The business has a 50-day moving average of $45.61 and a two-hundred day moving average of $56.15. The company has a market cap of $1.33 billion, a P/E ratio of 20.28, a P/E/G ratio of 2.11 and a beta of 1.32. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.19 and a quick ratio of 2.09.

BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings results on Tuesday, July 30th. The medical research company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.08. BioTelemetry had a return on equity of 22.98% and a net margin of 11.06%. The company had revenue of $111.80 million during the quarter, compared to analysts’ expectations of $111.11 million. During the same period last year, the business posted $0.46 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. Equities analysts anticipate that BioTelemetry Inc will post 1.98 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in BEAT. Two Sigma Advisers LP grew its holdings in BioTelemetry by 205.2% during the 4th quarter. Two Sigma Advisers LP now owns 9,900 shares of the medical research company’s stock worth $591,000 after acquiring an additional 6,656 shares during the last quarter. Geode Capital Management LLC grew its holdings in BioTelemetry by 11.8% during the 4th quarter. Geode Capital Management LLC now owns 376,618 shares of the medical research company’s stock worth $22,490,000 after acquiring an additional 39,722 shares during the last quarter. Huntington National Bank grew its holdings in BioTelemetry by 35.5% during the 1st quarter. Huntington National Bank now owns 680 shares of the medical research company’s stock worth $43,000 after acquiring an additional 178 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in BioTelemetry by 1.8% during the 1st quarter. State of Alaska Department of Revenue now owns 11,327 shares of the medical research company’s stock worth $709,000 after acquiring an additional 195 shares during the last quarter. Finally, Chartwell Investment Partners LLC bought a new stake in BioTelemetry during the 1st quarter worth approximately $1,072,000. Institutional investors own 90.84% of the company’s stock.

BioTelemetry Company Profile (NASDAQ:BEAT)

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Recommended Story: Dollar Cost Averaging

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.